August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Healthcare M&A faces tighter review as FTC retains guidelines
- Healthcare giants prioritize shareholder payouts over patient care
- Texas abortion ban linked to spike in pregnancy complications, maternal death
- AI streamlines documentation, frees time for nurses at Cedars-Sinai surgical unit
- Study identifies potential non-surgical treatment for inguinal hernias
- Rural hospital closures remain a growing concern despite slight financial improvement
- Session: Hoisting the Sails—Winning Strategies for Growing Service Lines in an ASC
- Session: Riding the Wave—Considerations to Making Anesthesia Profitable in Today's Labor Market
- Session: Surfs Up—Rolling Out the OAS CAHPS Survey
- Montana legislators' prior authorization reform push mirrors national trends
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement